TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03719157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous patient controlled analgesia
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous patient controlled analgesia
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous patient controlled analgesia
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravenous patient controlled analgesia
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
Study: NCT03237468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck strengthening exercise to prevent concussion
Description: Neck strengthening exercise to prevent concussion in student athletes.
Study: NCT00535925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC therapy
Description: the patients have to be treated according the standard good medical practice by any center

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan
Description: Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: Therapy for hypertension~- Step 3: amlodipine up to 10 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Description: Therapy for hypertension~- Step 4: atenolol up to 100 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin
Description: Therapy for hypertension~- Step 5: doxazosin up to 4 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Therapy for hypertension~- Step 6: clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Therapy for Hyperglycaemia (to achieve HbA1c \<7):~- insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Therapy for hypercholesterolemia:~- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrate
Description: Therapy for hypertriglyceridemia~- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Treatment of anaemia:~- erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: Antiplatelet therapy (in all patients without contraindications):~- aspirin up to 160 mg/die
Study: NCT02906072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low fat plant-based diet
Description: Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lectures on health effects of a low fat plant-based diet.
Description: Participants attend the lectures on health effects of a low fat plant-based diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lectures on health effects of a low fat plant-based diet.
Description: Participants attend the lectures on health effects of a low fat plant-based diet.
Study: NCT00476580

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questions to collect health information specific to Sri Lankans.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questions to collect health information specific to Sri Lankans.
Study: NCT02240043

Intervention type: OTHER
Group type: OTHER
Intervention: growth hormone secretion
Description: The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
Study: NCT03357393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is givenas sedation to the Control arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro
Description: Propofol is given as sedation to both intervention arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro
Description: Propofol is given as sedation to both intervention arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine-scopolamine
Description: Given as premedication for the Control arm and one of the interventions arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine-scopolamine
Description: Given as premedication for the Control arm and one of the interventions arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Given as premedication for one of the intervention arms..
Study: NCT03311048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Description: Nasal swab was collect to upper airways inflammation evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Description: Nasal swab was collect to upper airways inflammation evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Description: Nasal swab was collect to upper airways inflammation evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Description: Nasal swab was collect to upper airways inflammation evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
Study: NCT01228903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Xanthine oxidase inhibitor- effective at lowering uric acid levels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets with no active ingredient
Study: NCT02934438

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo40

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03390738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
Study: NCT00282841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: single intravenous administration of maximum 1.5 milliliter ultrasound contrast agent (Definity), followed by maximum 15 minutes transcranial insonation using diagnostic ultrasound.
Study: NCT03779022

Intervention type: GENETIC
Intervention: microRNA
Description: The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.

Intervention type: GENETIC
Intervention: microRNA
Description: The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
Study: NCT01798576

Intervention type: DRUG
Intervention: Pegylated Interferon alfa-2a
Description: Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
Study: NCT00864266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
Study: NCT01931059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We gave oral liquid without active risperidone (pt and provider were both double blinded)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We gave oral liquid without active risperidone (pt and provider were both double blinded)
Study: NCT02647073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canary 01 Mobile Vital Signs Monitoring Device
Description: The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
Study: NCT02427347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy education
Description: Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy education
Description: Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
Study: NCT03519542

Intervention type: DRUG
Intervention: Sunitinib
Description: Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
Study: NCT01507064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: tablets 200mg dosage: 400mg bid duration: 4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser ablation (LA)
Description: For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser ablation (LA)
Description: For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study: NCT01522846

Intervention type: DRUG
Intervention: Heparin
Description: Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
Study: NCT01966549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785
Description: CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
Study: NCT02000947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Study: NCT02629562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B12019 and Neulasta
Description: GCSF, Growth Colony Stimulating Factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B12019 and Neulasta
Description: GCSF, Growth Colony Stimulating Factor
Study: NCT01946815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
Study: NCT02714166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.

Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmic Ointment
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study: NCT03436615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 4%
Description: Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 8%
Description: Twice daily
Study: NCT01790243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Drug Coated Balloon
Description: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA Balloon
Description: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
Study: NCT00264459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen formulation
Description: Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
Study: NCT03436615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 12%
Description: Once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once or twice daily
Study: NCT03775876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Arthroscopy
Description: patients in both groups are programmed for an elective shoulder arthroscopy surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Arthroscopy
Description: patients in both groups are programmed for an elective shoulder arthroscopy surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block
Description: patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block
Description: patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol 10mg/ml was used for sedation as described in the arms section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: sedation level was monitored using bispectral index to achieve values described in the arms group

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: sedation level was monitored using bispectral index to achieve values described in the arms group
Study: NCT03607331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular vagus nerve stimulation
Description: Auricular vagus nerve stimulation is a typical representative of TCM modernization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
Study: NCT05936320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information leaflets with illustrations about hearing aid functions
Description: The information leaflet contains written information with simple illustrations about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information leaflets with only text about hearing aid functions
Description: The information leaflet contains written information about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
Study: NCT05156541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma human recombinant (IFN-G)
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT01469000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: 250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.